Status:
UNKNOWN
Optimal rhCG(Ovidrel®) Dose in Poor Responder During IVF and ICSI Cycles
Lead Sponsor:
Seoul National University Hospital
Conditions:
in Vitro Fertilization
Poor Responder
Eligibility:
FEMALE
21-44 years
Phase:
NA
Brief Summary
Choriogonadotropin alfa (Ovidrel®) is a recombinant hCG (rhCG) preparation derived from genetically engineered Chinese hamster ovary cells, which is widely used for final oocyte maturation triggering ...
Detailed Description
Randomized prospective clinical study that compare the two doses of rhCG (250mcg vs. 500mcg).
Eligibility Criteria
Inclusion
- poor response in prior IVF cycle (≤ 4 oocyte retrieved)
- women's age ≥ 40 years
- FSH ≥ 10mIU/mL or AMH ≤ 1.1ng/mL
- Antral follicle count \<6
Exclusion
- patient without informed consent
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2013
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01406600
Start Date
September 1 2011
End Date
December 1 2013
Last Update
April 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea, 110-744